SYM 2259

Drug Profile

SYM 2259

Alternative Names: SYM-2259

Latest Information Update: 06 Nov 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Annovis
  • Class Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Epilepsy; Neurological disorders

Most Recent Events

  • 06 Nov 2006 Discontinued - Preclinical for Epilepsy in USA (unspecified route)
  • 06 Nov 2006 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)
  • 04 Dec 2003 No development reported - Preclinical for Epilepsy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top